NeoGenomics (NASDAQ: NEO) reported Q4 EPS of $0.05, $0.03 better than the analyst estimate of $0.02. Revenue for the quarter came in at $27.3 million versus the consensus estimate of $26.46 million.

GUIDANCE:

NeoGenomics sees FY2016 EPS of $0.07-$0.12, versus the consensus of $0.07. NeoGenomics sees FY2016 revenue of $240-250 million, versus the consensus of $243.8 million.

For earnings history and earnings-related data on NeoGenomics (NEO) click here.